Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

ConditionsST-Segment Elevation Myocardial Infarction (STEMI)No-Reflow Phenomenon Coronary Slow Flow Acute Myocardial Infarction

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18-80

SponsorNational Institute of Cardiovascular Diseases, Pakistan

About this trial

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Eligibility criteria

Qualifiers

All patients with acute STEMI undergoing primary PCI

Patients of either sex, ≥18 years of age.

Disqualifiers

STEMI patients with cardiogenic shock at presentation

Patients with heart block

Allergy to adenosine

Patients refuse to give consent for participation

Trial design

Treatments tested in this trial

Adenosine pre-medication
Standard care

Treatment groups

1,148 Participants

are divided into 2 treatment groups

Locations

National Institute of Cardiovascular Diseases75510, KarachiSindh, Pakistan

Sponsors and collaborators

National Institute of Cardiovascular Diseases, Pakistan

Lead sponsor

Source ClinicalTrials.gov